Phaseline

Companies › Acerta Pharma

Acerta Pharma: clinical trials, targets and expected readouts

6 active drug programs in 75 registered trials: 48 Phase 2, 15 Phase 1, 12 Phase 3; Oncology, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Acalabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Lymphoma, Mantle Cell; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma (MCL) …Dec 2026
Rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Diffuse Large B-Cell LymphomaFeb 2027
Obinutuzumab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Chronic Lymphocytic LeukemiaApr 2027
Chlorambucil
Alkylating agent
–Phase 3Chronic Lymphocytic Leukemia; MALT Lymphoma–
ACP-319
Mechanism unclear
–Phase 1Chronic Lymphocytic Leukemia–
Ceralasertib (AZD6738)
Serine-protein kinase ATR inhibitor
ATRPhase 1Chronic Lymphocytic Leukemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02475681AcalabrutinibPhase 3Chronic Lymphocytic LeukemiaOncologyFeb 2019
NCT02475681ObinutuzumabPhase 3Chronic Lymphocytic LeukemiaOncologyFeb 2019
NCT02475681ChlorambucilPhase 3Chronic Lymphocytic LeukemiaOncologyFeb 2019
NCT02586857AcalabrutinibPhase 1Glioblastoma MultiformeOncologyJun 2020
NCT02157324AcalabrutinibPhase 1Chronic Lymphocytic LeukemiaOncologyJul 2020
NCT02157324ACP-319Phase 1Chronic Lymphocytic LeukemiaOncologyJul 2020
NCT02717611AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyOct 2020
NCT02213926AcalabrutinibPhase 2Mantle Cell Lymphoma (MCL)OncologyDec 2020
NCT03328273AcalabrutinibPhase 1Chronic Lymphocytic LeukemiaOncologySep 2021
NCT03328273Ceralasertib (AZD6738)Phase 1Chronic Lymphocytic LeukemiaOncologySep 2021
NCT05336812AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyOct 2026
NCT05065554AcalabrutinibPhase 2IgM MGUSNeurologyDec 2026
NCT02180724AcalabrutinibPhase 2Waldenström Macroglobulinemia (WM)OncologyDec 2026
NCT06757647AcalabrutinibPhase 2Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaOncologyDec 2026
NCT04115631AcalabrutinibPhase 2Liver LymphomaOncologyDec 2026
NCT04462328AcalabrutinibPhase 1Primary Central Nervous System LymphomaOncologyDec 2026
NCT05971251AcalabrutinibPhase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT05943496AcalabrutinibPhase 1Chronic Lymphocytic LeukemiaOncologyJan 2027
NCT05214183AcalabrutinibPhase 2MCLOncologyJan 2027
NCT04883437AcalabrutinibPhase 2Grade 1 Follicular LymphomaOncologyJan 2027
NCT04978584AcalabrutinibPhase 2Diffuse Large B-Cell LymphomaOncologyJan 2027
NCT05256641AcalabrutinibPhase 1Diffuse Large B-Cell LymphomaOncologyJan 2027
NCT04906902AcalabrutinibPhase 1Central Nervous System LymphomaOncologyJan 2027
NCT04657094AcalabrutinibPhase 2Autoimmune Hemolytic AnemiaOncologyFeb 2027
NCT02972840AcalabrutinibPhase 3Lymphoma, Mantle CellOncologyFeb 2027
NCT04722172AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyFeb 2027
NCT04529772AcalabrutinibPhase 3Diffuse Large B-Cell LymphomaOncologyFeb 2027
NCT04529772RituximabPhase 3Diffuse Large B-Cell LymphomaOncologyFeb 2027
NCT04484012AcalabrutinibPhase 2Recurrent Mantle Cell LymphomaOncologyFeb 2027
NCT03836261AcalabrutinibPhase 3Chronic Lymphocytic LeukemiaOncologyApr 2027
NCT04198922AcalabrutinibPhase 2Recurrent Moderate-Severe Chronic Graft Versus Host DiseaseOncologyApr 2027
NCT03836261ObinutuzumabPhase 3Chronic Lymphocytic LeukemiaOncologyApr 2027
NCT04002947AcalabrutinibPhase 2Non-Hodgkin's LymphomaOncologyMay 2027
NCT02029443AcalabrutinibPhase 1Chronic Lymphocytic LeukemiaOncologyJun 2027
NCT04189757AcalabrutinibPhase 2Mantle Cell LymphomaOncologyJun 2027
NCT04505254AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyJun 2027
NCT04855695AcalabrutinibPhase 1Mantle Cell LymphomaOncologyJun 2027
NCT06054776AcalabrutinibPhase 2Mantle Cell LymphomaOncologyJul 2027
NCT04783415AcalabrutinibPhase 2Mantle Cell LymphomaOncologyJul 2027
NCT04941716AcalabrutinibPhase 2Recurrent Chronic Lymphocytic LeukemiaOncologyAug 2027
NCT02717624AcalabrutinibPhase 1Mantle Cell Lymphoma (MCL)OncologyAug 2027
NCT04646395AcalabrutinibPhase 2Marginal Zone LymphomaOncologySep 2027
NCT02970318AcalabrutinibPhase 3Chronic Lymphocytic LeukemiaOncologyOct 2027
NCT04546620AcalabrutinibPhase 2Diffuse Large B Cell LymphomaOncologyNov 2027
NCT03580928AcalabrutinibPhase 2Chronic Lymphocytic Leukemia (CLL)OncologyDec 2027
NCT04624633AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyJan 2028
NCT02477696AcalabrutinibPhase 3Chronic Lymphocytic LeukemiaOncologyJan 2028
NCT03946878AcalabrutinibPhase 2Blastoid Variant Mantle Cell LymphomaOncologyFeb 2028
NCT04560322AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyMar 2028
NCT04404088AcalabrutinibPhase 2Ann Arbor Stage III Grade 1 Follicular LymphomaOncologyMar 2028
NCT05197192AcalabrutinibPhase 3Chronic Lymphocytic LeukemiaOncologyMay 2028
NCT03863184AcalabrutinibPhase 2Mantle Cell LymphomaOncologyMay 2028
NCT07014917AcalabrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyJun 2028
NCT05004064AcalabrutinibPhase 2Mantle Cell LymphomaOncologyJun 2028
NCT03899337AcalabrutinibPhase 2Richter SyndromeOncologyJun 2028
NCT04169737AcalabrutinibPhase 2Recurrent Chronic Lymphocytic LeukemiaOncologyJul 2028
NCT04963946AcalabrutinibPhase 2Untreated Chronic Lymphocytic LeukemiaOncologyAug 2028
NCT04626791AcalabrutinibPhase 2Mantle Cell LymphomaOncologyAug 2028
NCT04765111AcalabrutinibPhase 2Mantle Cell LymphomaOncologyAug 2028
NCT04566887AcalabrutinibPhase 2Mantle Cell LymphomaOncologySep 2028

The 60 nearest readouts of 75 trials; the rest in the app.

Targets

MS4A1 (2) BTK (1) ATR (1)

Companies with the same targets

Roche AstraZeneca Biocad Novartis Sanofi BeOne Medicines Eli Lilly Regeneron Pharmaceuticals Sandoz Celltrion

Companies built like this

Lepu Biopharma R-Pharm GC Cell Genfleet Therapeutics (Shanghai) Immunocore

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.